சிகிச்சை நோய் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share: DUBLIN, Ireland and TREVOSE, Pa., June 03, 2021 (GLOBE NEWSWIRE) Strongbridge Biopharma plc, (NASDAQ:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,020,393 entitled, Methods of Treating Disease with Levoketoconazole which covers a method of treating Cushing s syndrome patients with RECORLEV ® (levoketoconazole) who also take metformin for Type 2 diabetes. The term of the U.S. patent will expire on March 2, 2040. This will be the third patent issued in the U.S. relating to RECORLEV. The first, U.S. Patent No. 9,198,906, covers methods of reducing C-reactive protein levels and systemic inflammation through administration of a once-daily dose of RECORLEV and will expire on December 29, 2030. The second, U.S. patent No. 9,918,984, covers methods of

United statesMike biegaLindsay roccoStrongbridge biopharmaTrademark officeDrug administrationElixir health public relationsEuropean medicines agencyUnited states patentTreating diseaseNew drug applicationEuropean medicinesAnnual reportQuarterly reportsஒன்றுபட்டது மாநிலங்களில்மைக் பிஏக